Health Topics — Metabolic & Cognitive
Inflammation, Insulin Resistance, and the Endocannabinoid System: What the Research Shows
The adipose inflammatory pathway as a driver of insulin resistance — distinct from cortisol dysregulation — and where CB2 receptor activity, PPAR-γ, and the broader ECS intersect with this biology.
The connection between obesity, inflammation, and insulin resistance has been one of the most productive research areas in metabolic medicine since the 1990s. What emerged from that research is a picture significantly more complex than the simple energy-balance model of metabolic disease: adipose tissue is not passive storage but an active endocrine and immune organ, and its inflammatory output is a primary driver of insulin resistance that operates independently of — and in concert with — the cortisol pathway covered elsewhere in this archive.
This article covers the adipose inflammatory mechanism in the detail the research supports, its molecular intersection with insulin signalling, and where the endocannabinoid system — particularly CB2 receptor activity and PPAR-γ — sits within this biology.
Adipose Tissue as an Inflammatory Organ
The reclassification of adipose tissue from passive energy store to active endocrine organ is one of the more significant conceptual shifts in metabolic medicine. Adipocytes — fat cells — produce and release a range of biologically active molecules collectively called adipokines, which include both pro-inflammatory and anti-inflammatory signals. The balance of these signals changes substantially with adipose tissue expansion, particularly visceral adipose tissue expansion.
As visceral fat accumulates, two processes converge. First, expanding adipocytes become hypoxic — starved of oxygen as the tissue outgrows its blood supply — and this hypoxic stress triggers the release of pro-inflammatory signals. Second, macrophages — immune cells — are recruited into the adipose tissue in increasing numbers. In lean adipose tissue, macrophages represent approximately 5–10% of total cell count. In obese adipose tissue, this rises to 50–60%. These infiltrating macrophages adopt a pro-inflammatory phenotype and produce TNF-α and IL-6 at high levels.
The combined result is a chronically inflamed adipose depot releasing a sustained low-level inflammatory signal into systemic circulation — detectable in clinical bloodwork as elevated high-sensitivity CRP, elevated fasting IL-6, and other markers of low-grade systemic inflammation.
How TNF-α and IL-6 Block Insulin Signalling
The molecular mechanism by which adipose-derived inflammation produces insulin resistance is well characterised. TNF-α — tumour necrosis factor alpha — binds its receptor on insulin-sensitive cells in liver and muscle and activates the NF-κB (nuclear factor kappa B) inflammatory pathway. NF-κB activation triggers the production of serine kinases — enzymes that phosphorylate IRS-1 (insulin receptor substrate 1) at serine residues rather than tyrosine residues.
This serine phosphorylation of IRS-1 is the key molecular event. Under normal insulin signalling, the insulin receptor activates IRS-1 through tyrosine phosphorylation, which then propagates the signal downstream through PI3K and Akt to ultimately stimulate GLUT4 translocation — the movement of glucose transporters to the cell surface that allows glucose uptake. Serine phosphorylation of IRS-1 blocks this cascade at its second step. The insulin receptor is activated, but its signal does not propagate. The cell becomes insulin resistant at the molecular level.
IL-6 — interleukin-6 — contributes through a parallel mechanism, activating SOCS3 (suppressor of cytokine signalling 3), which directly inhibits IRS-1 function and promotes its degradation. Both cytokines therefore converge on the same insulin signalling bottleneck — IRS-1 function — through different upstream routes.
Distinguishing the Inflammatory Pathway from the Cortisol Pathway
The cortisol-insulin resistance pathway covered in the Cortisol-Metabolism Connection article operates primarily through glucocorticoid receptor signalling — cortisol binding to glucocorticoid receptors in insulin-sensitive tissue, suppressing GLUT4 expression, and inhibiting the IRS-1 signalling cascade at the level of phosphorylation state. The inflammatory pathway described here operates through cytokine receptor signalling — TNF-α and IL-6 activating NF-κB and SOCS3, converging on IRS-1 serine phosphorylation. These are distinct molecular mechanisms that produce the same functional outcome: insulin resistance. In most people with metabolic dysfunction, both pathways are active simultaneously and compound each other.
The Endocannabinoid System in Adipose Inflammation
CB1 and CB2 receptors are both expressed in adipose tissue and in the macrophages that infiltrate it. Their roles in the inflammatory metabolic context are distinct and in some respects opposing.
CB1 receptor overactivation in visceral adipose tissue has been consistently associated in preclinical models with increased lipogenesis — fat synthesis — reduced lipolysis — fat breakdown — and enhanced adipokine production including leptin. The endocannabinoid system becomes tonically overactive in obese adipose tissue, and this CB1 overactivation contributes to the inflammatory phenotype of the expanded adipose depot. This was the pharmacological rationale for rimonabant — the CB1 inverse agonist that produced significant metabolic improvements in clinical trials before being withdrawn for psychiatric side effects. The metabolic evidence from those trials confirmed that CB1 activity in adipose tissue is a meaningful contributor to the inflammatory metabolic state.
CB2 receptors, expressed on adipose tissue macrophages and on adipocytes themselves, show a contrasting profile. CB2 activation in preclinical models has been associated with reduced macrophage infiltration into adipose tissue, suppressed TNF-α and IL-6 production from macrophages, and improved inflammatory signalling in the adipose microenvironment. The mechanism involves CB2-mediated suppression of NF-κB activation — the same pathway that TNF-α uses to block insulin signalling — suggesting that CB2 activity in adipose macrophages could in principle reduce the upstream inflammatory signal that drives IRS-1 serine phosphorylation.
CBG is a partial agonist at CB2 receptors. Whether its partial agonism produces the anti-inflammatory macrophage effects documented with fuller CB2 agonists in preclinical models has not been directly tested in metabolic inflammation models. The mechanism is plausible; the CBG-specific evidence in this domain is limited to its PPAR-γ activity described below.
PPAR-γ as the Convergence Point
Peroxisome proliferator-activated receptor gamma (PPAR-γ) sits at a molecular convergence point between the inflammatory and metabolic pathways. It is a nuclear receptor — a transcription factor that, when activated, enters the nucleus and changes the expression of target genes — expressed in adipocytes, macrophages, and to a lesser extent in liver and muscle.
In adipocytes, PPAR-γ activation upregulates GLUT4 expression, promotes adiponectin production — an anti-inflammatory adipokine that improves insulin sensitivity — and suppresses the pro-inflammatory cytokine production that drives the NF-κB pathway. In macrophages, PPAR-γ activation suppresses NF-κB directly and shifts macrophage polarisation toward an anti-inflammatory phenotype — reducing the infiltrating macrophage's production of TNF-α and IL-6 at the source.
PPAR-γ is therefore anti-inflammatory and insulin-sensitising simultaneously through the same transcriptional mechanism. This is why pharmaceutical PPAR-γ agonists — the thiazolidinediones, including pioglitazone and rosiglitazone — were developed as type 2 diabetes treatments: they improve insulin sensitivity partly by reducing the adipose inflammatory signal that drives insulin resistance, not only by directly improving glucose transport.
CBG is a documented PPAR-γ agonist, established across multiple cell culture models and considered one of CBG's most consistently replicated preclinical pharmacological properties. In the metabolic inflammation context, CBG's PPAR-γ activity engages the same transcriptional mechanism that reduces adipose macrophage inflammatory output and improves adipocyte insulin sensitivity. Whether this preclinical mechanism operates at clinically meaningful levels in humans using hemp-derived CBG preparations is not established. The in vitro concentrations at which PPAR-γ activation has been documented may not be achievable through oral supplementation at standard doses — this is an honest gap in the translational evidence.
What This Research Establishes
Visceral adipose tissue produces TNF-α and IL-6 through infiltrating macrophages, activating NF-κB and SOCS3 pathways that block insulin signalling at IRS-1 — producing insulin resistance through a mechanism distinct from but compounding cortisol dysregulation. The ECS is present in this biology through CB1 activity in adipocytes, CB2 activity in adipose macrophages, and PPAR-γ as a shared transcriptional target. CBG's documented PPAR-γ agonism engages the most insulin-sensitising and anti-inflammatory node in this pathway. CB2's role in macrophage polarisation is mechanistically relevant to CBG's partial CB2 agonism. No human clinical trial of CBG for metabolic inflammation exists. The preclinical mechanisms are coherent and well-documented; translational gaps between cell culture concentrations and oral supplementation remain.
References
- Hotamisligil, G.S., Shargill, N.S., & Spiegelman, B.M. (1993). Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science, 259(5091), 87–91.
- Weisberg, S.P., et al. (2003). Obesity is associated with macrophage accumulation in adipose tissue. Journal of Clinical Investigation, 112(12), 1796–1808.
- Shoelson, S.E., Lee, J., & Goldfine, A.B. (2006). Inflammation and insulin resistance. Journal of Clinical Investigation, 116(7), 1793–1801.
- Olefsky, J.M., & Glass, C.K. (2010). Macrophages, inflammation, and insulin resistance. Annual Review of Physiology, 72, 219–246.
- Cota, D., et al. (2003). The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. Journal of Clinical Investigation, 112(3), 423–431.
- Verty, A.N., et al. (2015). Anti-obesity effect of the CB2 receptor agonist JWH-015 in diet-induced obese mice. PLOS ONE, 10(11), e0140592.
- Balistreri, C.R., Caruso, C., & Candore, G. (2010). The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediators of Inflammation, 2010, 802078.
- Rosen, E.D., & Spiegelman, B.M. (2001). PPAR-γ: a nuclear regulator of metabolism, differentiation, and cell growth. Journal of Biological Chemistry, 276(41), 37731–37734.
- Granja, A.G., et al. (2012). A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis. Journal of Neuroimmune Pharmacology, 7(4), 1002–1016.
These statements have not been evaluated by the Food and Drug Administration. J.P. Hemp Company products are not intended to diagnose, treat, cure, or prevent any disease.